Trial reportAntimicrobial agents and chemotherapy1997
Pharmacokinetics of gentamicin at traditional versus high doses: implications for once-daily aminoglycoside dosing.
Trial report in Antimicrobial agents and chemotherapy, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Impact of repeated intranasal gentamicin irrigation on structure and function of the vestibular brainstem.Experimental brain research · 2025Article
- Role of therapeutic drug monitoring in the treatment of multi-drug resistant tuberculosis.Journal of clinical tuberculosis and other mycobacterial diseases · 2024Article
- A Pharmacodynamic Study of Aminoglycosides against PathogenicPharmaceuticals (Basel, Switzerland) · 2023Article
- MPC-Based Prediction of Anti-Mutant Effectiveness of Antibiotic Combinations: In Vitro Model Study with Daptomycin and Gentamicin againstAntibiotics (Basel, Switzerland) · 2021Article
- Aminoglycosides in the Intensive Care Unit: What Is New in Population PK Modeling?Antibiotics (Basel, Switzerland) · 2021Review
- Verification of a Novel Approach to Predicting Effects of Antibiotic Combinations: In Vitro Dynamic Model Study with Daptomycin and Gentamicin againstAntibiotics (Basel, Switzerland) · 2020Article
- Identification of FDA-Approved Drugs with Activity against Stationary PhaseAntibiotics (Basel, Switzerland) · 2019Article
- Evaluation of daptomycin combinations with cephalosporins or gentamicin against Streptococcus mitis group strains in an in vitro model of simulated endocardial vegetations (SEVs).The Journal of antimicrobial chemotherapy · 2017Article
- Scaling clearance in paediatric pharmacokinetics: All models are wrong, which are useful?British journal of clinical pharmacology · 2017Article
- Evaluation of Amikacin Pharmacokinetics and Pharmacodynamics for Optimal Initial Dosing Regimen.Drugs in R&D · 2017Article
- Impact of a high loading dose of amikacin in patients with severe sepsis or septic shock.Annals of intensive care · 2016Article
- Article
- Population pharmacokinetics of gentamicin and dosing optimization for infants.Antimicrobial agents and chemotherapy · 2015Article
- Review
- Therapy of intracellular Staphylococcus aureus by tigecyclin.BMC infectious diseases · 2013Article
- Effects of obesity and sex on antimicrobial pharmacokinetics and acute kidney injury: validation of a preclinical model.Antimicrobial agents and chemotherapy · 2013Article
- Article
- Extended-interval aminoglycoside therapy for adult patients with febrile neutropenia: a systematic review.The Canadian journal of hospital pharmacy · 2011Article
- Antimicrobial breakpoints for gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation.The Journal of antimicrobial chemotherapy · 2008Article
- Activity of daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus assessed by time-kill methodology.Antimicrobial agents and chemotherapy · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Two doses of gentamicin (2 and 7 mg/kg of body weight) were administered to 11 healthy volunteers in a randomized, crossover single-dose study to compare their pharmacokinetics. Doses were infused over 1 h with a syringe infusion pump, and 14 concentrations in sera were obtained over an 8-h period. Concentration in serum versus time data were fitted to a two-compartment pharmacokinetic model. In addition, to mimic the clinical setting, subjects' data were fitted by the Sawchuk-Zaske method. Distributional and postdistributional peak concentrations, along with the last obtained concentration in serum, were utilized to compare the following pharmacokinetic variables: volume of distribution at steady state (Vss), half-life, clearance (CL), and maximum concentration in serum (Cmax). With two-compartment pharmacokinetic fitting, significant differences in distribution half-life (average, 21.8 and 41.6 min [P < or = 0.05]) and gentamicin CL (76.6 +/- 6.6 and 67.2 +/- 4.2 ml/min/1.73 m2 [P < or = 0.001]) were found between traditional-dose and high-dose groups, respectively. When the data for concentrations in sera were fitted to a one-compartment pharmacokinetic model by using either the distributional or the postdistributional Cmax, statistically significant differences (P < or = 0.001) were found between Vss, half-life, CL, and Cmax values for both dosage groups. The results show that the pharmacokinetics of gentamicin at a large dose differ significantly from those at the traditional dose. This information has direct implications for once-daily aminoglycoside (ODA) literature when the Cmax values reported are distributional and therefore show falsely high Cmax/MIC ratio estimates. In addition, ODA nomogram dosing tools developed with distributional Cmax values are probably inaccurate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.